跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 123 条关于
“BTKis”
全部
123
临床试验
100
药物
0
机构
0
资讯
23
9天前
Waldenström Macroglobulinemia Market Poised for Steady Growth Through 2036 on Novel BTK Degraders, Non-Covalent BTKis, and Targeted Radiotherapeutics
3个月前
Bexobrutideg Shows High Response Rates and Manageable Safety in BTK Degrader Trial for Relapsed/Refractory CLL
去年
Expert Panel Debates Treatment Strategies for High-Risk Relapsed CLL Patient with Cardiac Complications
2年前
Relma-cel CAR-T Therapy Approved in China for Relapsed/Refractory Mantle Cell Lymphoma
去年
Fixed-Duration Venetoclax Regimen Reduces Long-Term Costs in CLL Treatment
去年
Zanubrutinib and Venetoclax Combination Shows Promise in Relapsed/Refractory CLL
2年前
Global CLL Trial Landscape Shows Robust Activity, Highlights Regional Disparities
去年
Zanubrutinib Demonstrates Durable Efficacy and Favorable Safety in CLL/SLL Treatment
去年
Ascentage Pharma's Lisaftoclax Receives Priority Review in China for Relapsed/Refractory CLL/SLL
去年
China's NMPA Accepts Ascentage Pharma's NDA for Lisaftoclax in R/R CLL/SLL with Priority Review
第 1 页,共 3 页
上一页
下一页